Last reviewed · How we verify
Fosfomycun-trometamol
Fosfomycin trometamol is a broad-spectrum antibiotic that inhibits bacterial cell wall synthesis by blocking peptidoglycan cross-linking.
Fosfomycin trometamol is a broad-spectrum antibiotic that inhibits bacterial cell wall synthesis by blocking peptidoglycan cross-linking. Used for Uncomplicated urinary tract infections (acute cystitis), Bacterial urinary tract infections in women.
At a glance
| Generic name | Fosfomycun-trometamol |
|---|---|
| Sponsor | University Hospital, Rouen |
| Drug class | Phosphonic acid antibiotic |
| Target | MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Fosfomycin trometamol works by inhibiting the enzyme MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), which is essential for the early stages of bacterial peptidoglycan synthesis. This disruption of cell wall formation leads to bacterial cell death. The trometamol salt formulation enhances oral bioavailability and urinary concentration, making it particularly effective for urinary tract infections.
Approved indications
- Uncomplicated urinary tract infections (acute cystitis)
- Bacterial urinary tract infections in women
Common side effects
- Diarrhea
- Nausea
- Headache
- Vaginitis
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fosfomycun-trometamol CI brief — competitive landscape report
- Fosfomycun-trometamol updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI